Cantor Fitzgerald Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $480
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer maintains an Overweight rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raises the price target from $440 to $480.
July 22, 2024 | 3:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has maintained an Overweight rating on Vertex Pharmaceuticals and increased the price target from $440 to $480, indicating strong confidence in the company's future performance.
The increase in the price target from $440 to $480 by a reputable analyst suggests a positive outlook for Vertex Pharmaceuticals. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100